Last checked at 5 Apr 2016 07:00
05 April 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Investor Evening - Thursday 5 May 2016
A discussion of its proprietary Affimer technology and an update on commercial and therapeutic strategies
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that it will be hosting an investor evening at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, on Thursday 5 May 2016 from 17.00-20.30 BST. The Company will discuss its proprietary Affimer technology and provide an update on the progress made against its commercial and therapeutic goals. Chief Executive Officer Alastair Smith will be joined by Philippe Cotrel, Amrik Basran, Matt Johnson and Tony Gardiner from the Company's Senior Leadership Team.
Drinks and canapés will be served following the Company's presentations.
For further information and to reserve a place at the event please contact: avacta@fticonsulting.com
Enquiries:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com |
Numis Securities Limited Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking
WG Partners David Wilson Nigel Barnes Claes Spang
| Tel: +44 (0) 207 260 1000 www.numiscorp.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk
|
Media Enquiries FTI Consulting Simon Conway / Natalie Garland-Collins | Tel: +44 (0) 203 727 1000 avacta@fticonsulting.com |
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate these markets, worth in excess of $75bn, despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be generated quickly to bind with high specificity and affinity to a wide range of biological and chemical targets.
Avacta has an in-house pre-clinical Affimer therapeutic development programme with a focus on immuno-oncology and bleeding disorders and has several partnered development programmes including a major research partnership with Moderna Therapeutics.
Avacta is also commercialising Affimer reagents for research and diagnostics through custom Affimer services to provide bespoke solutions to customers and via a small on-line catalogue of Affimer reagents.